Accurus Biosciences Overview
- Year Founded
-
2012
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
1
Accurus Biosciences General Information
Description
Operator of a biotechnology company intended to develop protein therapeutics for antibody discovery process. The company offers stable cell line generation, cell-based assay and recombinant protein production services on contract basis, enabling clients to expedite their research efficiently.
Contact Information
Website
www.accurusbio.comCorporate Office
- 2600 Hilltop Drive
- Suite C337, Building B
- Richmond, CA 94806
- United States
Corporate Office
- 2600 Hilltop Drive
- Suite C337, Building B
- Richmond, CA 94806
- United States
Accurus Biosciences Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Accelerator/Incubator | Completed | Startup |
Accurus Biosciences Comparisons
Industry
Financing
Details
Accurus Biosciences Competitors (4)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
ABclonal Yurogen | Formerly Accelerator/Incubator backed | Worcester, MA | ||||
Absolute Antibody | Private Equity-Backed | Redcar, United Kingdom | ||||
DJS Antibodies | Formerly VC-backed | Bicester, United Kingdom | ||||
Oak Biosciences | Corporation | Sunnyvale, CA |
Accurus Biosciences Patents
Accurus Biosciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3826612-A1 | Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof | Pending | 25-Jul-2018 | ||
EP-3826612-A4 | Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof | Pending | 25-Jul-2018 | ||
US-20210214433-A1 | Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof | Active | 25-Jul-2018 | ||
US-12054543-B2 | Cldn 18.2-specific monoclonal antibodies and methods of use thereof | Active | 25-Jul-2018 | ||
US-11634490-B2 | Blocking antibodies against cd47 and methods of use thereof | Active | 15-Jun-2018 | C07K16/2803 |
Accurus Biosciences Executive Team (2)
Name | Title | Board Seat |
---|---|---|
Richard Zhang Ph.D | Founder & Chief Executive Officer | |
Haishan Lin Ph.D | President |
Accurus Biosciences Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
QB3 | Accelerator/Incubator |
Accurus Biosciences FAQs
-
When was Accurus Biosciences founded?
Accurus Biosciences was founded in 2012.
-
Who is the founder of Accurus Biosciences?
Richard Zhang Ph.D is the founder of Accurus Biosciences.
-
Who is the CEO of Accurus Biosciences?
Richard Zhang Ph.D is the CEO of Accurus Biosciences.
-
Where is Accurus Biosciences headquartered?
Accurus Biosciences is headquartered in Richmond, CA.
-
What industry is Accurus Biosciences in?
Accurus Biosciences’s primary industry is Biotechnology.
-
Is Accurus Biosciences a private or public company?
Accurus Biosciences is a Private company.
-
What is Accurus Biosciences’s current revenue?
The current revenue for Accurus Biosciences is
. -
Who are Accurus Biosciences’s investors?
QB3 has invested in Accurus Biosciences.
-
Who are Accurus Biosciences’s competitors?
ABclonal Yurogen, Absolute Antibody, DJS Antibodies, and Oak Biosciences are competitors of Accurus Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »